モキシデクチン

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiparasitic Agents; Anthelmintics; Antinematodal Agents; Insecticides; Macrolides

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Antifilarials

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 81 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

In the large, controlled trial of moxidectin vs ivermectin in onchocerciasis, transient serum aminotransferase elevations were found in 22% of moxidectin- and 21% of ivermectin-treated participants which were above 3 times ULN in 1.2% vs 1.6%. Bilirubin levels were also frequently elevated (9.9% vs 9.5%) but were transient resolving in all patients. Thus, the liver test abnormalities were invariably transient, mild to moderate in severity, and appeared to be part of the Mazzotti reaction, resolving within days or weeks of onset. No patient developed what could be considered clinically apparent liver injury. Since approval of moxidectin as therapy of onchocerciasis in humans, there have been no reports of liver injury with symptoms or jaundice associated with its use. There have also been no reports of liver injury with use of moxidectin in other human parasitic infections [such as Strongyloides stercoralis] where liver test abnormalities were no more frequent with moxidectin than with placebo.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Moxidectin

Ambiguous-DILI-concern

P - Antiparasitic products, insecticides and repellents

QP - Antiparasitic products, insecticides and repellents

Moxidectin has been reported to be highly effective against _Onchocerca volvulus_ when compared to ivermectin. When moxidectin was administered in infected individuals, the microfilarial load in the skin was lower even when compared to the current therapy, ivermectin. The levels of microfilarial got reduced to an undetectable level while being safe to be used in mass drug administration.

Moxidectin selectively binds to the parasite's GABA-A and glutamate-gated chloride ion channels which are vital for the function of invertebrate nerve and muscle cells. It presents activity against the parasite but it does not kill him. Once moxidectin is bound, there is an increased permeability leading to an influx of chloride ions and flaccid paralysis of the parasite.

Reports have registered enzymatic modification in humans and in nematodes. In the case of moxidectin, there has been registered C29-30- and C14-mono-hydroxymethyl derivatives mainly by the cytochrome CYP3A and CYP2B. The metabolism of moxidectin is considered to contribute to a small extent to the elimination. Some other metabolites formed are O-demethyl-dihydroxy metabolites. The metabolism of the of moxidectin is not major as the major residue in fat, liver, kidney and muscle is the unchanged moxidectin.

Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal.

Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.